<!DOCTYPE article
PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD with MathML3 v1.3 20210610//EN" "JATS-archivearticle1-3-mathml3.dtd">
<article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" dtd-version="1.3" xml:lang="en" article-type="research-article"><?properties open_access?><processing-meta base-tagset="archiving" mathml-version="3.0" table-model="xhtml" tagset-family="jats"><restricted-by>pmc</restricted-by></processing-meta><front><journal-meta><journal-id journal-id-type="nlm-ta">Ecancermedicalscience</journal-id><journal-id journal-id-type="iso-abbrev">Ecancermedicalscience</journal-id><journal-id journal-id-type="publisher-id">ecancermedicalscience</journal-id><journal-title-group><journal-title>ecancermedicalscience</journal-title></journal-title-group><issn pub-type="epub">1754-6605</issn><publisher><publisher-name>Cancer Intelligence</publisher-name></publisher></journal-meta>
<article-meta><article-id pub-id-type="pmid">40177148</article-id><article-id pub-id-type="pmc">PMC11959135</article-id>
<article-id pub-id-type="doi">10.3332/ecancer.2025.1832</article-id><article-id pub-id-type="publisher-id">can-19-1832</article-id><article-categories><subj-group subj-group-type="heading"><subject>Research</subject></subj-group></article-categories><title-group><article-title>Real-world data on the efficacy and toxicity of induction chemotherapy in locally advanced nasopharyngeal carcinoma in a non-endemic population</article-title></title-group><contrib-group><contrib contrib-type="author"><name><surname>Hidalgo Filho</surname><given-names>Cassio Murilo</given-names></name><xref rid="aff1" ref-type="aff">1</xref><xref rid="aff4" ref-type="aff">a</xref></contrib><contrib contrib-type="author"><name><surname>Polho</surname><given-names>Gabriel Berlingieri</given-names></name><xref rid="aff1" ref-type="aff">1</xref></contrib><contrib contrib-type="author"><name><surname>Moreira</surname><given-names>Otavio Augusto</given-names></name><xref rid="aff1" ref-type="aff">1</xref></contrib><contrib contrib-type="author"><name><surname>Andrade</surname><given-names>Matheus de Oliveira</given-names></name><xref rid="aff1" ref-type="aff">1</xref></contrib><contrib contrib-type="author"><name><surname>Parrela</surname><given-names>Vinicius Cruz</given-names></name><xref rid="aff1" ref-type="aff">1</xref></contrib><contrib contrib-type="author"><name><surname>Shinkado</surname><given-names>Yumi Ricucci</given-names></name><xref rid="aff1" ref-type="aff">1</xref></contrib><contrib contrib-type="author"><name><surname>de Almeida Robatto</surname><given-names>Amanda Acioli</given-names></name><xref rid="aff1" ref-type="aff">1</xref></contrib><contrib contrib-type="author"><name><surname>Neto</surname><given-names>Felippe Lazar</given-names></name><xref rid="aff1" ref-type="aff">1</xref></contrib><contrib contrib-type="author"><name><surname>Freitas</surname><given-names>Ana Julia</given-names></name><xref rid="aff2" ref-type="aff">2</xref></contrib><contrib contrib-type="author"><name><surname>Souza</surname><given-names>Aurelio Teixeira</given-names></name><xref rid="aff3" ref-type="aff">3</xref></contrib><contrib contrib-type="author"><name><surname>de Castro Junior</surname><given-names>Gilberto</given-names></name></contrib><contrib contrib-type="author"><name><surname>Mak</surname><given-names>Milena Perez</given-names></name><xref rid="aff1" ref-type="aff">1</xref></contrib><aff id="aff1">
<label>1</label>Department of Clinical Oncology, Instituto do Cancer do Estado de S&#x000e3;o Paulo ICESP, Hospital das Clinicas HCFMUSP, Faculdade de Medicina, Universidade de S&#x000e3;o Paulo, S&#x000e3;o Paulo, SP 05508-220, Brazil</aff><aff id="aff2">
<label>2</label>Barretos Cancer Hospital, S&#x000e3;o Paulo, SP 14784-400, Brazil</aff><aff id="aff3">
<label>3</label>Department of Radiotherapy, Instituto do Cancer do Estado de S&#x000e3;o Paulo ICESP, Hospital das Clinicas HCFMUSP, Faculdade de Medicina, Universidade de S&#x000e3;o Paulo, S&#x000e3;o Paulo, SP 05508-220, Brazil</aff><aff id="aff4">
<label>a</label><ext-link xlink:href="https://orcid.org/0000-0002-7046-0059" ext-link-type="uri">https://orcid.org/0000-0002-7046-0059</ext-link></aff></contrib-group><author-notes><corresp id="c1-can-19-1832"><bold>Correspondence to:</bold> Cassio Murilo Hidalgo Filho <email>cmtrovohidalgo@gmail.com</email></corresp></author-notes><pub-date pub-type="collection"><year>2025</year></pub-date><pub-date pub-type="epub"><day>23</day><month>1</month><year>2025</year></pub-date><volume>19</volume><elocation-id>1832</elocation-id><history><date date-type="received"><day>20</day><month>7</month><year>2024</year></date></history><permissions><copyright-statement>&#x000a9; the authors; licensee <italic>e</italic>cancermedicalscience.</copyright-statement><copyright-year>2025</copyright-year><license><ali:license_ref xmlns:ali="http://www.niso.org/schemas/ali/1.0/" specific-use="textmining" content-type="ccbylicense">https://creativecommons.org/licenses/by/4.0/</ali:license_ref><license-p>This is an Open Access article distributed under the terms of the Creative Commons Attribution License (<ext-link xlink:href="https://creativecommons.org/licenses/by/4.0/" ext-link-type="uri">http://creativecommons.org/licenses/by/4.0</ext-link>), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.</license-p></license></permissions><abstract><sec><title>Background</title><p>Induction chemotherapy (ICT) is critical for managing locally advanced nasopharyngeal carcinoma (LA-NPC), but real-world data on its efficacy and toxicity are limited.</p></sec><sec sec-type="methods"><title>Methods</title><p>This retrospective study included LA-NPC patients treated with ICT from 2012 to 2022. We evaluated radiological response rates, overall survival (OS), treatment-related toxicities and complete response (CR) rates.</p></sec><sec><title>Results</title><p>Among 217 patients, 119 met the inclusion criteria and were included in the final analysis. CR rates were similar across ICT regimens (docetaxel, cisplatin and 5-fluorouracil 68.0%; cisplatin and gemcitabine 57.1%; cisplatin and 5-fluorouracil 58.0%; others 50%, <italic>p</italic> = 0.72). Serious adverse events (SAEs) occurred in 22%, with 69.7% experiencing weight loss and 31.9% requiring enteral tube placement. Poor OS was linked to Eastern Cooperative Oncology Group performance status (ECOG-PS) &#x02265;2 hazard ratios (HR 2.8, <italic>p</italic> = 0.004) and residual disease (RD) (HR 7.4, <italic>p</italic> = 0.001). Stage IV (Odds Ratio [OR] 3.77, p = 0.005) and ECOG-PS &#x02265; 2 (OR 4.69, <italic>p</italic> = 0.006) were associated with RD.</p></sec><sec><title>Conclusion</title><p>ICT regimens had similar CR rates. Poor ECOG-PS and stage IV predicted RD. Managing toxicities is crucial for better outcomes.</p></sec></abstract><kwd-group><kwd>nasopharynx</kwd><kwd>carcinoma</kwd><kwd>chemotherapy</kwd><kwd>real-world data</kwd><kwd>LMIC</kwd></kwd-group></article-meta></front><body><sec><title>Introduction</title><p>Nasopharyngeal carcinoma (NPC) stands as a unique and challenging entity within the spectrum of head and neck malignancies, characterised by its distinct epidemiological patterns, etiological factors and clinical behaviour [<xref rid="ref1" ref-type="bibr">1</xref>]. Recently, there has been a growing interest in exploring novel therapeutic strategies to improve outcomes. Induction chemotherapy (ICT) is considered the standard of care for patients with locally advanced disease [<xref rid="ref2" ref-type="bibr">2</xref>].</p><p>ICT, as a therapeutic strategy, holds an essential role in the management of locally advanced nasopharyngeal carcinoma (LA-NPC). By administering systemic chemotherapy before definitive local treatments, such as radiotherapy (RT) or concurrent chemoradiotherapy (CRT), ICT aims to reduce tumour burden, eradicate micrometastases and enhance the overall efficacy of subsequent treatments. The rationale behind this approach lies in its potential to target both the primary tumour and disseminated disease, ultimately optimising the chances of locoregional control and distant metastasis prevention. Additionally, response to ICT predicts the benefit of definitive local treatment [<xref rid="ref3" ref-type="bibr">3</xref>, <xref rid="ref4" ref-type="bibr">4</xref>].</p><p>The choice of ICT regimen is influenced by both efficacy and toxicity considerations [<xref rid="ref5" ref-type="bibr">5</xref>, <xref rid="ref6" ref-type="bibr">6</xref>]. Notably, comprehensive trials directly comparing the outcomes of different ICT regimens are scarce. Thus, selecting the most appropriate ICT becomes challenging for clinicians managing LA-NPC cases. There is a need for more evidence-based guidance in this aspect, urging for trials that systematically assess and compare various ICT regimens [<xref rid="ref7" ref-type="bibr">7</xref>].</p><p>Currently, there is limited data on the outcomes of the different ICT options available for NPC among patients in Latin America. This study addresses this gap by evaluating the outcomes of treated NPC patients with ICT at a tertiary cancer center in Brazil, emphasising the differences in efficacy and toxicity profiles among different ICT regimens.</p></sec><sec sec-type="materialsandmethods"><title>Materials and methods</title><sec><title>Study design and population</title><p>This retrospective cohort study included patients diagnosed with LA-NPC at Instituto do Cancer do Estado de S&#x000e3;o Paulo, Brazil, a large tertiary cancer center in Latin America, from January 2012 to December 2022. We used the International Classification of Diseases (ICD-10) &#x02018;C11&#x02019; criteria to identify those patients with NPC. We included patients who received at least one cycle of planned ICT for LA-NPC. Exclusion criteria comprised (i) de novo metastatic NPC, (ii) concurrent head and neck malignant lesions, (iii) neuroendocrine or small cell carcinoma histologies and (iv) induction treatment information unavailable (e.g., treated outside the institution).</p></sec><sec><title>Data collection</title><p>Data for this retrospective cohort study were gathered from electronic health records. The collected data were anonymised and securely stored in REDCap, United States. The extracted variables encompassed demographic and clinical parameters, including sex, age at diagnosis, patient-reported race, Eastern Cooperative Oncology Group performance status (ECOG-PS) at the time of diagnosis, histology, Epstein-Barr virus (EBV) tumour positivity and tobacco exposure (considered present if the patient reported more than 100 cigarettes over their lifetime), body mass index at diagnosis. Moreover, TNM staging (AJCC 8th edition) and detailed information about the treatment, such as the ICT regimen chosen by the physician, the number of chemotherapy cycles, concurrent CRT regimen and RT doses, when available. During the study period, Image-Guided Intensity Modulated Radiation Therapy was consistently applied to all patients receiving RT. The occurrences of serious adverse events (SAEs) during ICT and CRT following the initial ICT were evaluated. SAEs were considered events during ICT or CRT that led patients to hospitalisation or death.</p><p>The dataset was enriched with information regarding the type of recurrence (locoregional, distant or both) and toxicities experienced during the treatment, such as (i) enteral feeding (any time of the treatment), (ii) severe mucositis (defined as mucositis interfering oral intake), (iii) weight loss of &#x02265;10% of the baseline, (iv) increase in creatinine levels for more than &#x0003e;2 mg/dL of the baseline and (v) incidence of febrile neutropenia. The last follow-up date for each patient was determined as the most recent contact with the healthcare provider and was updated on 11 March 2024. Hospital staff diligently documented deaths outside the hospital's medical records, ensuring a comprehensive and accurate representation of patient outcomes.</p></sec><sec><title>Outcomes</title><p>The primary objectives of this study were to describe the efficacy and explore outcomes related to the toxicity of different ICT regimens for patients with LA-NPC. Efficacy was measured through comprehensive radiological and clinical evaluations of treatment responses, while toxicity profiles were analyzed to understand the safety implications of each regimen.</p><p>Additionally, secondary outcomes included overall survival (OS) and recurrence-free survival (RFS) by ICT type. Also, the detailed description of definitive therapy (CRT or exclusive RT) after ICT and the attainment of complete radiological response (CR) or residual disease (RD) across different treatment groups. All imaging studies were reviewed by radiologists specialised in head and neck cancers. Head and neck cancer oncologists retrospectively evaluated the radiological response. The first image (computed tomography or magnetic resonance imaging) within at least 8&#x02013;12 weeks after the completion of CRT was considered for response evaluation.</p></sec><sec><title>Statistical analysis</title><p>Descriptive statistics were employed to characterise the numeric variables. Measures such as mean, standard deviation, median or interquartile range (IQR) were utilised based on the distribution of each variable. Categorical variables were presented using absolute numbers and proportions, expressed as percentages and compared with the Fisher and chi-square tests. Logistic regression tested the relation between the CR rate and different independent variables. Only statistically significant variables were included in the multivariate analysis. Mortality rates were estimated for the overall patient cohort, among different induction therapy regimens and between patients with and without recurrence. RFS was calculated from the first ICT doses to the occurrence of a recurrence confirmed by imaging. OS was calculated from the date of the first chemotherapy doses to the occurrence of death or the last follow-up. In cases where no event occurred, patients were censored at the last follow-up date. Hazard ratios (HRs) for OS were calculated using Cox proportional hazard models. Survival and time probabilities were estimated using the Kaplan-Meier method. The statistical analyses were executed utilising R for Statistical Computing (Vienna, Austria) version 4.2.1 (2022-06-23).</p></sec><sec><title>Ethical approval</title><p>This study received ethical approval from the local ethics committee, under approval number 49094921.4.0000.0068, in compliance with ethical standards and patient confidentiality.</p></sec></sec><sec><title>Results</title><sec><title>Patients' characteristics</title><p>A total of 217 patients were initially identified through the ICD filter. After applying the study criteria, 119 patients were included in the final analysis (<xref rid="figure3" ref-type="fig">Supplementary Figure S1</xref>). Among the included patients, the median age was 49.5 years old (IQR 29.5&#x02013;58.7). Most (59.7%) were male and self-referred as white (74%). The majority had ECOG-PS 0-1 (84.7%) and stage IV disease (71.4%).</p><p>The most prevalent histology in the cohort was undifferentiated non-keratinising carcinoma (WHO type 3), corresponding to 58% of the patients, followed by keratinising squamous cell carcinoma (WHO type 1) (33%). The EBV status was tested by <italic>in situ</italic> hybridisation in 62% and found positive in 55 patients, corresponding to 46% of the entire cohort. Detailed patient characteristics are presented in <xref rid="table1" ref-type="table">Table 1</xref>.</p></sec><sec><title>Treatment details</title><p>The most prescribed ICT regimen was cisplatin and gemcitabine (CG), followed by cisplatin and 5-fluorouracil (CF) and docetaxel, cisplatin and 5-fluorouracil (TPF) (41%, 26% and 21%, respectively). Among other regimens of induction therapy by physician&#x02019;s choice, seven patients received carboplatin and paclitaxel (CP) (5.8%), five carboplatin and 5-fluorouracil (4.2%) and two patients received CP followed by CG (<xref rid="table2" ref-type="table">Table 2</xref>). Most of our cohort underwent concurrent CRT (89%) with cisplatin 100 mg per m<sup>2</sup> (mg/m<sup>2</sup>) every 3 weeks (98%). Only two patients received cisplatin 40 mg/m<sup>2</sup> weekly.</p><p>RT alone was performed for nine patients due to poor performance status after induction therapy. Four patients received only one cycle of ICT and no further treatment. Three of them died after the ICT, two due to rapid progressive cancer and one due to sepsis. One patient lost follow-up after one cycle. The median RT duration was 7.0 weeks (IQR 6.57&#x02013;7.86), while approximately 90% received more than 6 weeks of CRT and the planned dosing of 7000 cGY.</p><p>Among the patients who did not complete the full course of CRT, the main reason was toxicity, especially during the last third of the treatment course. Of the 44 patients who did not complete CRT, 33 (75%) stopped due to toxicity, 8 (18.2%) were lost to follow-up or had treatment compliance issues, 2 (4.5%) chose not to continue treatment and 1 (2.3%) discontinued due to disease progression.</p><p>Patients with ECOG PS &#x02265;2 (<italic>n</italic> = 17) experienced significantly lower treatment compliance compared to the overall cohort. Only 29.4% completed the full course of CRT. Notably these patients also had more advanced disease at the diagnosis (<xref rid="table6" ref-type="table">Supplementary Table S1</xref>).</p></sec><sec><title>Toxicity profile</title><p>SAEs leading to hospitalisation occurred in 22% of the entire cohort. During the treatment, 69.7% of the patients experienced weight loss &#x02265;10% of the baseline. Mucositis leading to decreased oral intake occurred in 53.8%, and 31.9% required an enteral tube placement for feeding during the treatment. In addition, increased creatinine levels (10.1%) or febrile neutropenia (5.9%) were also reported. There were no statistically significant differences in toxicities among different ICT regimens. However, CF was associated with numerically more weight loss (80.6%) and enteral feeding (34.5%) than other ICT choices. CG was associated with numerically less mucositis (42.8% versus 64% versus 61.2%) and enteral feeding than TPF and CF (26.5% versus 32% versus 35.4%). Despite the distinct toxicity profiles, CRT completion rates were similar among different induction regimens (<italic>p</italic> = 0.33). The details of treatment toxicity are described in <xref rid="table2" ref-type="table">Table 2</xref>.</p></sec><sec><title>Patients&#x02019; outcomes</title><p>Most patients achieved radiological response (<xref rid="table3" ref-type="table">Table 3</xref>). Radiological CR rates were similar among ICT regimens (TPF 68.0%; CG 57.1%; CF 58.0%; others 50%, <italic>p</italic> = 0.72) (<xref rid="figure4" ref-type="fig">Supplementary Figure S2</xref>). There was no difference in CR rate among different histologies (<italic>p</italic> = 0.75), completion of CRT (<italic>p</italic> = 0.83) or EBV status (<italic>p</italic> = 0.18). In the univariate logistic regression, factors that increased the odds of RD after ICT followed by a definite treatment were: Stage IV (Odds Ratio (OR) 3.77, 95% CI 1.54&#x02013;10.2, <italic>p</italic> = 0.005), SAEs (OR 3.19, 95% CI 1.32&#x02013;8.00, <italic>p</italic> = 0.01) and ECOG-PS &#x02265;2 (OR 4.69 95% CI 1.63&#x02013;15.6, <italic>p</italic> = 0.006). There was no difference in CR rate between keratinising versus non-keratinising histologies, completion of CRT or EBV positivity status (<xref rid="table4" ref-type="table">Table 4</xref>). In multivariate analysis, ECOG-PS &#x02265;2 (OR 3.96, 95% CI 1.33&#x02013;13.4, <italic>p</italic> = 0.017) and stage IV (OR 3.29, 95% CI 1.32&#x02013;9.11, <italic>p</italic> = 0.014) remained significant.</p><p>Among the patients who experienced disease recurrence (36.9%), distant recurrence was more common (63.6%) than locoregional recurrence (29.5%). Additionally, a small proportion of patients had both distant and locoregional recurrences (6.8%). The RFS rates varied among the ICT regimens. The 12-month RFS was 95.3% (95% CI 88.1&#x02013;100.0) for TPF, 83.2% (95% CI 73.2&#x02013;94.5) for CG, 76.8% (95% CI 63.0&#x02013;93.4) for CF and 64.3% (95% CI 43.5&#x02013;95.0) for other regimens. However, no statistical difference was observed among them (<italic>p</italic> = 0.1) (<xref rid="figure1" ref-type="fig">Figure 1</xref>).</p><p>The OS for the entire cohort was 87.5 months (CI 95% 64.9&#x02013;122.0). The median follow-up time was 64.6 months. In the univariate Cox regression analysis, ECOG-PS &#x02265;2 (<italic>p</italic> = 0.004) and incomplete radiological response (<italic>p</italic> &#x0003c; 0.001) were associated with lower OS rates. However, no significant OS differences were observed based on the chemotherapy regimen (<xref rid="figure2" ref-type="fig">Figure 2</xref>, <italic>p</italic> = 0.45), the occurrence of SAEs (<italic>p</italic> = 0.2) or the completion of CRT (<italic>p</italic> = 0.8) (<xref rid="table5" ref-type="table">Table 5</xref>).</p></sec></sec><sec><title>Discussion</title><p>In this study, we provided data about the outcomes of patients with LA-NPC who underwent ICT in a large cancer center in Brazil and the largest cohort described in Latin America. There was no difference in survival or toxicities among different ICT regimens. Patients with poor ECOG-PS experienced worse outcomes. In addition, ECOG-PS &#x02265;2, stage IV and the occurrence of SAEs were associated with RD after ICT followed by a definitive treatment, including CRT or isolated RT. CG regimen showed a more favourable toxicity profile, including less mucositis and a lower rate of enteral tube placement during the treatment.</p><p>The current standard of care for patients with LA-NPC includes CRT in combination with induction therapy or CRT, followed by adjuvant chemotherapy [<xref rid="ref8" ref-type="bibr">8</xref>]. Currently, no randomised trials comparing both strategies have been performed. Previous phase III clinical trials have tested various ICT regimens (CF, CG or TPF) in combination with CRT, each compared to CRT alone and demonstrated improved survival [<xref rid="ref9" ref-type="bibr">9</xref>&#x02013;<xref rid="ref11" ref-type="bibr">11</xref>]. However, clinical trials have mainly included patients from Asia, where NPC is endemic. There is little representativeness of the Latin American population in NPC trials evaluating induction systemic therapy. Although a low incidence of this malignancy is observed in Latin America, recent data indicated that the incidence and mortality of NPC have been increasing in low and middle-income Latin American nations, especially Brazil, in the last three decades [<xref rid="ref12" ref-type="bibr">12</xref>, <xref rid="ref13" ref-type="bibr">13</xref>]. Also, few retrospective series have addressed the outcomes of Brazilian patients diagnosed with NPC [<xref rid="ref14" ref-type="bibr">14</xref>, <xref rid="ref15" ref-type="bibr">15</xref>]. In our cohort, despite nonkeratinising carcinoma (WHO type 3) being the most prevalent histology, keratinising squamous cell carcinoma (WHO type 1) corresponded to a representative number, one-third of the cases, which was a higher proportion than what was observed in Finland [<xref rid="ref16" ref-type="bibr">16</xref>] and the Netherlands [<xref rid="ref17" ref-type="bibr">17</xref>], but similar to a previous report of a national database in the United States [<xref rid="ref18" ref-type="bibr">18</xref>]. There is a low number of patients tested for EBV positivity in the tumour, and it was positive for approximately 72% of patients with available EBV status. Our data suggests that the EBV positivity status was lower than previous data from another Brazilian study [<xref rid="ref19" ref-type="bibr">19</xref>]. Finally, our study differs from other cohorts in Latin America by including only LA-NPC patients and evaluating the outcomes related to each ICT regimen.</p><p>The current optimal ICT regimen still needs to be clarified, and oncologists base their therapy choice on each combination's efficacy and toxicity profile [<xref rid="ref20" ref-type="bibr">20</xref>]. Our study shows that most patients experienced significant weight loss, as observed in other studies evaluating patients with similar therapies [<xref rid="ref21" ref-type="bibr">21</xref>]. We also reported that severe mucositis (53.8%) and enteral feeding (31.9%) were relatively common findings, supporting previous data acknowledging RT-induced mucositis's association with malnutrition and weight loss [<xref rid="ref22" ref-type="bibr">22</xref>&#x02013;<xref rid="ref24" ref-type="bibr">24</xref>]. Moreover, our real-world data reveal substantial toxicity rates, which are often higher than those reported in clinical trials due to the controlled environments and stringent patient selection criteria of trials. We observed significant rates of weight loss, mucositis and the need for enteral feeding during treatment, emphasising the importance of proactive management strategies to mitigate treatment-related adverse events. These findings underscore the multidisciplinary nature of NPC care. Effective supportive care interventions are crucial for optimising treatment outcomes in the real-world setting.</p><p>It is essential to acknowledge the limitations of our study. First, it was conducted retrospectively, which may introduce biases and limit the ability to draw causal conclusions. Furthermore, in the context of global oncology, access to certain diagnostic tests, such as EBV status, may be limited and as a result, EBV testing was not available for all patients in our study, despite its known strong association with NPC. However, diagnoses were made by a specialised multidisciplinary team, including pathologists, radiologists, head and neck surgeons and oncologists, which likely ensured accuracy. The retrospective collection of toxicity profiles from medical records may have resulted in underreporting of adverse events, which could affect the overall interpretation of our findings. Detailed adverse event data, such as those classified under CTCAE, were not consistently available, which is usually a limitation of retrospective studies. Finally, the response evaluation was performed at distinct times and with different radiological methods (computed tomography scans or magnetic resonance imaging), and positron emission tomography &#x02013; computed tomography scan was not routinely used for response evaluation. Nevertheless, our study provides valuable real-world data to the limited body of literature on NPC management in a non-endemic country, highlighting the need for further research to refine treatment strategies and improve patient outcomes in this region.</p></sec><sec><title>Conclusion</title><p>In conclusion, this study suggests no significant differences in CR rates or survival outcomes among different ICT regimens in the studied population. Patients with distant recurrence and poor ECOG-PS experienced worse survival outcomes. The study suggests that ECOG-PS &#x02265;2, SAEs and stage IV are associated with a lower chance of CR, emphasising the importance of early detection and effective management of treatment adverse events. The study also provides valuable insights into the toxicity profiles of different ICT regimens, highlighting the need for multidisciplinary approaches to manage treatment-related events effectively. Overall, the study contributes to understanding NPC management and underscores the importance of further research to optimise treatment strategies and improve patient outcomes.</p></sec><sec sec-type="COI-statement"><title>Conflicts of interest</title><p><bold>Cassio Murilo Hidalgo Filho, Matheus de Oliveira Andrade, Vinicius Cruz Parrela, Yumi Ricucci Shinkado, Amanda Acioli de Almeida, Felippe Lazar Neto, Ana Julia Freitas</bold>, <bold>Aurelio Teixeira Souza</bold>: Declare no conflict of interest.</p><p>
<bold>Otavio Augusto Moreira:</bold>
</p><p><bold>Honoraria</bold>: Bayer, Novartis, Astrazeneca.</p><p><bold>Gilberto de Castro Junior</bold>: <bold>Honoraria:</bold> AstraZeneca, Pfizer, Merck Sharp &#x00026; Dohme, Bristol Myers Squibb, Novartis, Roche, Amgen, Janssen, Merck Serono, Lilly, Takeda, Daiichi Sankyo/UCB Japan</p><p><bold>Consulting or Advisory Role:</bold> Boehringer Ingelheim, Pfizer, Bayer, Roche, Merck Sharp &#x00026; Dohme, Bristol Myers Squibb, AstraZeneca, Yuhan, Merck Serono, Janssen, Libbs, Sanofi, Novartis, Lilly, Takeda, Daiichi Sankyo/UCB Japan</p><p><bold>Speakers' Bureau:</bold> AstraZeneca, Bayer, Novartis, Roche, Merck Serono, Bristol Myers Squibb, Merck Sharp &#x00026; Dohme, Boehringer Ingelheim, Pfizer, Janssen, Amgen, Takeda</p><p><bold>Travel, Accommodations, Expenses:</bold> Merck Sharp &#x00026; Dohme, Novartis, Pfizer, Roche, AstraZeneca, Boehringer Ingelheim, Bayer, Bristol Myers Squibb, Merck Serono, Daiichi Sankyo/UCB Japan</p><p>
<bold>Milena Perez Mak:</bold>
</p><p><bold>Honoraria:</bold> Bayer, Pfizer, Merck Serono, Takeda, Amgen Consulting or Advisory Role: AstraZeneca.</p></sec><sec><title>Funding</title><p>No funding was received for this study.</p></sec><sec><title>Author contributions</title><p><bold>Cassio Murilo Hidalgo Filho:</bold> Conceptualisation, methodology, project administration, supervision, data collection, visualisation, formal analysis, writing original draft, writing review and editing. <bold>Gabriel Berlingieri Polho:</bold> Methodology, project administration, supervision, data collection, visualisation, formal analysis, writing original draft, writing review and editing.</p><p><bold>Matheus de Oliveira Andrade, Vinicius Cruz Parrela, Yumi Ricucci Shinkado, Amanda Acioli de Almeida:</bold> Supervision, data collection, visualisation, writing review and editing. <bold>Felippe Lazar Neto:</bold> Supervision, visualisation, formal analysis, writing review and editing. <bold>Ana Julia Freitas:</bold> Methodology, formal analysis, writing review and editing. <bold>Aurelio Teixeira Souza:</bold> Supervision, visualisation, writing review and editing.<bold> Gilberto de Castro Junior</bold>: Conceptualisation, methodology, project administration, supervision, visualisation, writing review and editing. <bold>Milena Perez Mak:</bold> Conceptualisation, methodology, project administration, supervision, visualisation, writing review and editing.</p></sec></body><back><ack><title>Acknowledgments</title><p>The authors acknowledge all health professionals in the Head and Neck Oncology department at the Instituto do Cancer do Estado de Sao Paulo, Brazil. The authors would like to acknowledge the RT team for providing data for this study, especially Dr. Gabriel Faria Najas. This study used no funding sources.</p></ack><fn-group><fn><p>Publication costs for this article were supported by <italic>e</italic>cancer (UK Charity number 1176307).</p></fn></fn-group><ref-list><title>References</title><ref id="ref1"><label>1.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Chen</surname><given-names>YP</given-names></name><name><surname>Chan</surname><given-names>ATC</given-names></name><name><surname>Le</surname><given-names>QT</given-names></name><etal/></person-group><article-title>Nasopharyngeal carcinoma</article-title><source>Lancet</source><year>2019</year><volume>394</volume><fpage>64</fpage><lpage>80</lpage><pub-id pub-id-type="doi">10.1016/S0140-6736(19)30956-0</pub-id><pub-id pub-id-type="pmid">31178151</pub-id>
</element-citation></ref><ref id="ref2"><label>2.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Chen</surname><given-names>R</given-names></name><name><surname>Lu</surname><given-names>Y</given-names></name><name><surname>Zhang</surname><given-names>Y</given-names></name><etal/></person-group><article-title>Comparison of therapeutic efficacy and toxicity of docetaxel, cisplatin, and fluorouracil (TPF)-based induction chemotherapy plus concurrent chemoradiotherapy and chemoradiotherapy alone in locally advanced nasopharyngeal carcinoma</article-title><source>Medicine (Baltimore)</source><year>2021</year><volume>100</volume><fpage>e27475</fpage><pub-id pub-id-type="doi">10.1097/MD.0000000000027475</pub-id><!--<pub-id pub-id-type="pmcid">8542149</pub-id>--><pub-id pub-id-type="pmid">34678878</pub-id>
</element-citation></ref><ref id="ref3"><label>3.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bongiovanni</surname><given-names>A</given-names></name><name><surname>Vagheggini</surname><given-names>A</given-names></name><name><surname>Fausti</surname><given-names>V</given-names></name><etal/></person-group><article-title>Induction chemotherapy plus concomitant chemoradiotherapy in nasopharyngeal carcinoma: an updated network meta-analysis</article-title><source>Crit Rev Oncol Hematol</source><year>2021</year><volume>160</volume><fpage>103244</fpage><pub-id pub-id-type="doi">10.1016/j.critrevonc.2021.103244</pub-id><pub-id pub-id-type="pmid">33582249</pub-id>
</element-citation></ref><ref id="ref4"><label>4.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Yang</surname><given-names>SS</given-names></name><name><surname>Guo</surname><given-names>JG</given-names></name><name><surname>Liu</surname><given-names>JN</given-names></name><etal/></person-group><article-title>Effect of induction chemotherapy in nasopharyngeal carcinoma: an updated meta-analysis</article-title><source>Front Oncol</source><year>2021</year><volume>10</volume><fpage>591205</fpage><pub-id pub-id-type="doi">10.3389/fonc.2020.591205</pub-id><!--<pub-id pub-id-type="pmcid">7820771</pub-id>--><pub-id pub-id-type="pmid">33489889</pub-id>
</element-citation></ref><ref id="ref5"><label>5.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Li</surname><given-names>WZ</given-names></name><name><surname>Lv</surname><given-names>X</given-names></name><name><surname>Hu</surname><given-names>D</given-names></name><etal/></person-group><article-title>Effect of induction chemotherapy with paclitaxel, cisplatin, and capecitabine vs cisplatin and fluorouracil on failure-free survival for patients with stage IVA to IVB nasopharyngeal carcinoma: a multicenter phase 3 randomized clinical trial</article-title><source>JAMA Oncol</source><year>2022</year><volume>8</volume><fpage>706</fpage><lpage>714</lpage><pub-id pub-id-type="doi">10.1001/jamaoncol.2022.0122</pub-id><!--<pub-id pub-id-type="pmcid">8949760</pub-id>--><pub-id pub-id-type="pmid">35323856</pub-id>
</element-citation></ref><ref id="ref6"><label>6.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zong</surname><given-names>JF</given-names></name><name><surname>Lin</surname><given-names>PJ</given-names></name><name><surname>Tsou</surname><given-names>HH</given-names></name><etal/></person-group><article-title>Comparison the acute toxicity of two different induction chemotherapy schedules with cisplatin and fluorouracil in nasopharyngeal carcinoma patients</article-title><source>Radiother Oncol</source><year>2023</year><volume>184</volume><fpage>109699</fpage><pub-id pub-id-type="doi">10.1016/j.radonc.2023.109699</pub-id><pub-id pub-id-type="pmid">37169301</pub-id>
</element-citation></ref><ref id="ref7"><label>7.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wu</surname><given-names>Q</given-names></name><name><surname>Li</surname><given-names>S</given-names></name><name><surname>Liu</surname><given-names>J</given-names></name><etal/></person-group><article-title>Optimal induction chemotherapy regimen for locoregionally advanced nasopharyngeal carcinoma: an update Bayesian network meta-analysis</article-title><source>Eur Arch Otorhinolaryngol</source><year>2022</year><volume>279</volume><fpage>5057</fpage><lpage>5069</lpage><pub-id pub-id-type="doi">10.1007/s00405-022-07435-2</pub-id><pub-id pub-id-type="pmid">35767064</pub-id>
</element-citation></ref><ref id="ref8"><label>8.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ribassin-Majed</surname><given-names>L</given-names></name><name><surname>Marguet</surname><given-names>S</given-names></name><name><surname>Lee</surname><given-names>AWM</given-names></name><etal/></person-group><article-title>What is the best treatment of locally advanced nasopharyngeal carcinoma? An individual patient data network meta-analysis</article-title><source>J Clin Oncol</source><year>2017</year><volume>35</volume><fpage>498</fpage><lpage>505</lpage><pub-id pub-id-type="doi">10.1200/JCO.2016.67.4119</pub-id><pub-id pub-id-type="pmid">27918720</pub-id>
</element-citation></ref><ref id="ref9"><label>9.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zhang</surname><given-names>Y</given-names></name><name><surname>Chen</surname><given-names>L</given-names></name><name><surname>Hu</surname><given-names>GQ</given-names></name><etal/></person-group><article-title>Final overall survival analysis of gemcitabine and cisplatin induction chemotherapy in nasopharyngeal carcinoma: a multicenter, randomized phase III trial</article-title><source>J Clin Oncol</source><year>2022</year><volume>40</volume><fpage>2420</fpage><lpage>2425</lpage><pub-id pub-id-type="doi">10.1200/JCO.22.00327</pub-id><pub-id pub-id-type="pmid">35709465</pub-id>
</element-citation></ref><ref id="ref10"><label>10.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sun</surname><given-names>Y</given-names></name><name><surname>Li</surname><given-names>WF</given-names></name><name><surname>Chen</surname><given-names>NY</given-names></name><etal/></person-group><article-title>Induction chemotherapy plus concurrent chemoradiotherapy versus concurrent chemoradiotherapy alone in locoregionally advanced nasopharyngeal carcinoma: a phase 3, multicentre, randomised controlled trial</article-title><source>Lancet Oncol</source><year>2016</year><volume>17</volume><fpage>1509</fpage><lpage>1520</lpage><pub-id pub-id-type="doi">10.1016/S1470-2045(16)30410-7</pub-id><pub-id pub-id-type="pmid">27686945</pub-id>
</element-citation></ref><ref id="ref11"><label>11.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Yang</surname><given-names>Q</given-names></name><name><surname>Cao</surname><given-names>SM</given-names></name><name><surname>Guo</surname><given-names>L</given-names></name><etal/></person-group><article-title>Induction chemotherapy followed by concurrent chemoradiotherapy versus concurrent chemoradiotherapy alone in locoregionally advanced nasopharyngeal carcinoma: long-term results of a phase III multicentre randomised controlled trial</article-title><source>Eur J Cancer</source><year>2019</year><volume>119</volume><fpage>87</fpage><lpage>96</lpage><pub-id pub-id-type="doi">10.1016/j.ejca.2019.07.007</pub-id><pub-id pub-id-type="pmid">31425966</pub-id>
</element-citation></ref><ref id="ref12"><label>12.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Song</surname><given-names>Y</given-names></name><name><surname>Cheng</surname><given-names>W</given-names></name><name><surname>Li</surname><given-names>H</given-names></name><etal/></person-group><article-title>The global, regional, national burden of nasopharyngeal cancer and its attributable risk factors (1990&#x02013;2019) and predictions to 2035</article-title><source>Cancer Med</source><year>2022</year><volume>11</volume><fpage>4310</fpage><lpage>4320</lpage><pub-id pub-id-type="doi">10.1002/cam4.4783</pub-id><!--<pub-id pub-id-type="pmcid">9678109</pub-id>--><pub-id pub-id-type="pmid">35475595</pub-id>
</element-citation></ref><ref id="ref13"><label>13.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Romagna</surname><given-names>DV</given-names></name><name><surname>Oliveira</surname><given-names>MM</given-names></name><name><surname>Abreu</surname><given-names>LG</given-names></name><etal/></person-group><article-title>Incidence and mortality rates of lip, oral cavity, and pharynx cancers in Brazil: time-trend and age-period-cohort analysis from the last 30 years, Global Burden of Disease Study</article-title><source>Rev Soc Bras Med Trop</source><year>2021</year><volume>55</volume><fpage>e0286</fpage></element-citation></ref><ref id="ref14"><label>14.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Chedid</surname><given-names>HM</given-names></name><name><surname>Franzi</surname><given-names>SA</given-names></name><name><surname>Dedivitis</surname><given-names>RA</given-names></name></person-group><article-title>Avalia&#x000e7;&#x000e3;o dos fatores cl&#x000ed;nicos e do tratamento em pacientes com carcinoma indiferenciado da nasofaringe</article-title><source>Rev Bras Otorrinolaringol</source><year>2008</year><volume>74</volume><fpage>566</fpage><lpage>570</lpage><pub-id pub-id-type="doi">10.1590/S0034-72992008000400013</pub-id></element-citation></ref><ref id="ref15"><label>15.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Farias</surname><given-names>TP</given-names></name><name><surname>Dias</surname><given-names>FL</given-names></name><name><surname>Lima</surname><given-names>RA</given-names></name><etal/></person-group><article-title>Prognostic factors and outcome for nasopharyngeal carcinoma</article-title><source>Arch Otolaryngol Neck Surg</source><year>2003</year><volume>129</volume><fpage>794</fpage><lpage>799</lpage><pub-id pub-id-type="doi">10.1001/archotol.129.7.794</pub-id></element-citation></ref><ref id="ref16"><label>16.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ruuskanen</surname><given-names>M</given-names></name><name><surname>Irjala</surname><given-names>H</given-names></name><name><surname>Minn</surname><given-names>H</given-names></name><etal/></person-group><article-title>Epstein-Barr virus and human papillomaviruses as favorable prognostic factors in nasopharyngeal carcinoma: a nationwide study in Finland</article-title><source>Head Neck</source><year>2019</year><volume>41</volume><fpage>349</fpage><lpage>357</lpage><pub-id pub-id-type="doi">10.1002/hed.25450</pub-id><pub-id pub-id-type="pmid">30549170</pub-id>
</element-citation></ref><ref id="ref17"><label>17.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>van Velsen</surname><given-names>JS</given-names></name><name><surname>Vegt</surname><given-names>B</given-names></name><name><surname>Plaat</surname><given-names>BEC</given-names></name><etal/></person-group><article-title>Nasopharyngeal carcinoma: nationwide trends in subtype-specific incidence and survival over 3 decades in a non-endemic area</article-title><source>J Cancer Res Clin Oncol</source><year>2024</year><volume>150</volume><fpage>49</fpage><pub-id pub-id-type="doi">10.1007/s00432-023-05547-8</pub-id><!--<pub-id pub-id-type="pmcid">10824861</pub-id>--><pub-id pub-id-type="pmid">38285234</pub-id>
</element-citation></ref><ref id="ref18"><label>18.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ou</surname><given-names>SHI</given-names></name><name><surname>Zell</surname><given-names>JA</given-names></name><name><surname>Ziogas</surname><given-names>A</given-names></name><etal/></person-group><article-title>Epidemiology of nasopharyngeal carcinoma in the United States: improved survival of Chinese patients within the keratinizing squamous cell carcinoma histology</article-title><source>Ann Oncol</source><year>2007</year><volume>18</volume><fpage>29</fpage><lpage>35</lpage><pub-id pub-id-type="doi">10.1093/annonc/mdl320</pub-id><pub-id pub-id-type="pmid">17060483</pub-id>
</element-citation></ref><ref id="ref19"><label>19.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Dias</surname><given-names>JM</given-names></name><name><surname>Santana</surname><given-names>IVV</given-names></name><name><surname>Silva</surname><given-names>VD</given-names></name><etal/></person-group><article-title>Analysis of Epstein&#x02013;Barr Virus (EBV) and PD-L1 expression in nasopharyngeal carcinoma patients in a non-endemic region</article-title><source>Int J Mol Sci</source><year>2022</year><volume>23</volume><fpage>11720</fpage><pub-id pub-id-type="doi">10.3390/ijms231911720</pub-id><pub-id pub-id-type="pmid">36233023</pub-id>
</element-citation></ref><ref id="ref20"><label>20.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Felice</surname><given-names>FD</given-names></name><name><surname>Cirillo</surname><given-names>A</given-names></name><name><surname>Botticelli</surname><given-names>A</given-names></name></person-group><article-title>Ideal regimen for induction chemotherapy in nasopharyngeal cancer: still a hot issue?</article-title><source>Radiother Oncol</source><year>2022</year><volume>177</volume><fpage>111</fpage><lpage>112</lpage><pub-id pub-id-type="doi">10.1016/j.radonc.2022.10.033</pub-id><pub-id pub-id-type="pmid">36336112</pub-id>
</element-citation></ref><ref id="ref21"><label>21.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Leelasawatsuk</surname><given-names>P</given-names></name><name><surname>Prapaisit</surname><given-names>U</given-names></name><name><surname>Chaiyarukjirakun</surname><given-names>V</given-names></name><etal/></person-group><article-title>Long-term monitoring and predictive factors of critical weight loss among patients with nasopharyngeal carcinoma in a curative treatment setting</article-title><source>Am J Otolaryngol</source><year>2022</year><volume>43</volume><fpage>103407</fpage><pub-id pub-id-type="doi">10.1016/j.amjoto.2022.103407</pub-id><pub-id pub-id-type="pmid">35210108</pub-id>
</element-citation></ref><ref id="ref22"><label>22.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Arribas</surname><given-names>L</given-names></name><name><surname>Hurt&#x000f3;s</surname><given-names>L</given-names></name><name><surname>Taberna</surname><given-names>M</given-names></name><etal/></person-group><article-title>Nutritional changes in patients with locally advanced head and neck cancer during treatment</article-title><source>Oral Oncol</source><year>2017</year><volume>71</volume><fpage>67</fpage><lpage>74</lpage><pub-id pub-id-type="doi">10.1016/j.oraloncology.2017.06.003</pub-id><pub-id pub-id-type="pmid">28688694</pub-id>
</element-citation></ref><ref id="ref23"><label>23.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Huang</surname><given-names>JF</given-names></name><name><surname>Sun</surname><given-names>RJ</given-names></name><name><surname>Jiang</surname><given-names>WJ</given-names></name><etal/></person-group><article-title>Systematic nutrition management for locally advanced nasopharyngeal carcinoma patients undergoing radiotherapy</article-title><source>OncoTargets Ther</source><year>2019</year><volume>12</volume><fpage>8379</fpage><lpage>8386</lpage><pub-id pub-id-type="doi">10.2147/OTT.S213789</pub-id></element-citation></ref><ref id="ref24"><label>24.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Shu</surname><given-names>Z</given-names></name><name><surname>Zeng</surname><given-names>Z</given-names></name><name><surname>Yu</surname><given-names>B</given-names></name></person-group><article-title>Nutritional status and its association with radiation-induced oral mucositis in patients with nasopharyngeal carcinoma during radiotherapy: a prospective study</article-title><source> Front Oncol</source><year>2020</year><volume>10</volume><fpage>594687</fpage><pub-id pub-id-type="doi">10.3389/fonc.2020.594687</pub-id><!--<pub-id pub-id-type="pmcid">7677572</pub-id>--><pub-id pub-id-type="pmid">33240818</pub-id>
</element-citation></ref></ref-list><app-group><app><label>Supplementary material</label><fig position="anchor" id="figure3"><label>Supplementary Figure S1.</label><caption><title>Flow chart of patients included in the study.</title></caption><graphic xlink:href="can-19-1832fig3" position="float"/></fig><fig position="anchor" id="figure4"><label>Supplementary Figure S2.</label><caption><title>Radiological CR rate by ICT regimen among patients with LA-NPC. CRT: chemoradiotherapy, TPF: docetaxel, cisplatin and 5-fluorouracil, CG: Cisplatin + Gemcitabine, CF: Cisplatin + 5-fluorouracil.</title></caption><graphic xlink:href="can-19-1832fig4" position="float"/></fig><table-wrap position="anchor" id="table6"><label>Supplementary Table S1.</label><caption><title>Patients with ECOG-PS &#x02265;2 demographic characteristics and treatment details.</title></caption><table frame="border" rules="all"><thead><tr><th align="center" valign="top" rowspan="1" colspan="1">Characteristic</th><th align="left" valign="top" rowspan="1" colspan="1"/><th align="center" valign="top" rowspan="1" colspan="1">
<italic>n</italic>
</th><th align="center" valign="top" rowspan="1" colspan="1">%</th></tr></thead><tbody><tr><td align="left" valign="top" rowspan="2" colspan="1">Staging</td><td align="left" valign="top" rowspan="1" colspan="1">IV</td><td align="center" valign="top" rowspan="1" colspan="1">15</td><td align="center" valign="top" rowspan="1" colspan="1">88.24</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">III</td><td align="center" valign="top" rowspan="1" colspan="1">2</td><td align="center" valign="top" rowspan="1" colspan="1">11.76</td></tr><tr><td align="left" valign="top" rowspan="2" colspan="1">Sex</td><td align="left" valign="top" rowspan="1" colspan="1">Male</td><td align="center" valign="top" rowspan="1" colspan="1">14</td><td align="center" valign="top" rowspan="1" colspan="1">82.35</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Female</td><td align="center" valign="top" rowspan="1" colspan="1">3</td><td align="center" valign="top" rowspan="1" colspan="1">17.65</td></tr><tr><td align="left" valign="top" rowspan="2" colspan="1">Race</td><td align="left" valign="top" rowspan="1" colspan="1">White</td><td align="center" valign="top" rowspan="1" colspan="1">11</td><td align="center" valign="top" rowspan="1" colspan="1">64.70</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Other</td><td align="center" valign="top" rowspan="1" colspan="1">6</td><td align="center" valign="top" rowspan="1" colspan="1">35.30</td></tr><tr><td align="left" valign="top" rowspan="2" colspan="1">Histology</td><td align="left" valign="top" rowspan="1" colspan="1">Keratinizing squamous cell carcinoma</td><td align="center" valign="top" rowspan="1" colspan="1">10</td><td align="center" valign="top" rowspan="1" colspan="1">58.82</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Undifferentiated nonkeratinizing carcinoma</td><td align="center" valign="top" rowspan="1" colspan="1">7</td><td align="center" valign="top" rowspan="1" colspan="1">41.18</td></tr><tr><td align="left" valign="top" rowspan="3" colspan="1">EBV</td><td align="left" valign="top" rowspan="1" colspan="1">Positive</td><td align="center" valign="top" rowspan="1" colspan="1">6</td><td align="center" valign="top" rowspan="1" colspan="1">35.30</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Negative</td><td align="center" valign="top" rowspan="1" colspan="1">2</td><td align="center" valign="top" rowspan="1" colspan="1">11.76</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Unavailable</td><td align="center" valign="top" rowspan="1" colspan="1">9</td><td align="center" valign="top" rowspan="1" colspan="1">52.94</td></tr><tr><td align="left" valign="top" rowspan="2" colspan="1">Tabagism</td><td align="left" valign="top" rowspan="1" colspan="1">Yes</td><td align="center" valign="top" rowspan="1" colspan="1">10</td><td align="center" valign="top" rowspan="1" colspan="1">58.82</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">No</td><td align="center" valign="top" rowspan="1" colspan="1">7</td><td align="center" valign="top" rowspan="1" colspan="1">41.18</td></tr><tr><td align="left" valign="top" rowspan="3" colspan="1">Treatment performed</td><td align="left" valign="top" rowspan="1" colspan="1">CRT</td><td align="center" valign="top" rowspan="1" colspan="1">10</td><td align="center" valign="top" rowspan="1" colspan="1">58.82</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">RT monotherapy</td><td align="center" valign="top" rowspan="1" colspan="1">3</td><td align="center" valign="top" rowspan="1" colspan="1">17.65</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">ICT only<xref rid="table6_fn1" ref-type="table-fn">*</xref></td><td align="center" valign="top" rowspan="1" colspan="1">4</td><td align="center" valign="top" rowspan="1" colspan="1">23.53</td></tr><tr><td align="left" valign="top" rowspan="2" colspan="1">Recurrence</td><td align="left" valign="top" rowspan="1" colspan="1">Yes</td><td align="center" valign="top" rowspan="1" colspan="1">9</td><td align="center" valign="top" rowspan="1" colspan="1">52.94</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">No</td><td align="center" valign="top" rowspan="1" colspan="1">8</td><td align="center" valign="top" rowspan="1" colspan="1">47.06</td></tr><tr><td align="left" valign="top" rowspan="2" colspan="1">Death</td><td align="left" valign="top" rowspan="1" colspan="1">Yes</td><td align="center" valign="top" rowspan="1" colspan="1">10</td><td align="center" valign="top" rowspan="1" colspan="1">58.82</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">No</td><td align="center" valign="top" rowspan="1" colspan="1">7</td><td align="center" valign="top" rowspan="1" colspan="1">41.18</td></tr></tbody></table><table-wrap-foot><fn id="table6_fn1"><label>*</label><p>Three patients died during ICT and one patient lost follow-up after first cycle of ICT</p></fn><p>ECOG: Eastern Cooperative Oncology Group performance status, ICT: induction chemotherapy, CRT: chemoradiotherapy, RT: radiotherapy, EBV: Epstein Barr virus</p></table-wrap-foot></table-wrap></app></app-group></back><floats-group><fig position="float" id="figure1"><label>Figure 1.</label><caption><title>RFS according to ICT among patients with LA-NPC. TPF: docetaxel, cisplatin and 5-fluorouracil, CG: Cisplatin + Gemcitabine, CF: Cisplatin + 5-fluorouracil.</title></caption><graphic xlink:href="can-19-1832fig1" position="float"/></fig><fig position="float" id="figure2"><label>Figure 2.</label><caption><title>OS according to ICT among patients with LA-NPC. TPF: docetaxel, cisplatin and 5-fluorouracil, CG: Cisplatin + Gemcitabine, CF: Cisplatin + 5-fluorouracil.</title></caption><graphic xlink:href="can-19-1832fig2" position="float"/></fig><table-wrap position="float" id="table1"><label>Table 1.</label><caption><title>Clinical characteristics of patients diagnosed with LA-NPC treated with ICT.</title></caption><table frame="border" rules="all"><thead><tr><th align="center" valign="middle" rowspan="1" colspan="1">Characteristic</th><th align="center" valign="middle" rowspan="1" colspan="1">Mean</th><th align="center" valign="middle" rowspan="1" colspan="1">Median</th><th align="center" valign="middle" rowspan="1" colspan="1">IQR</th><th align="center" valign="middle" rowspan="1" colspan="1">Percentile 25</th><th align="center" valign="middle" rowspan="1" colspan="1">Percentile 75</th><th align="center" valign="middle" rowspan="1" colspan="1">SD</th></tr></thead><tbody><tr><td align="left" valign="middle" rowspan="1" colspan="1">
<bold>Age</bold>
</td><td align="center" valign="middle" rowspan="1" colspan="1">45.83</td><td align="center" valign="middle" rowspan="1" colspan="1">49.52</td><td align="center" valign="middle" rowspan="1" colspan="1">29.27</td><td align="center" valign="middle" rowspan="1" colspan="1">29.5</td><td align="center" valign="middle" rowspan="1" colspan="1">58.77</td><td align="center" valign="middle" rowspan="1" colspan="1">16.65</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">
<bold>Smoking history (pack/years)</bold>
</td><td align="center" valign="middle" rowspan="1" colspan="1">32.38</td><td align="center" valign="middle" rowspan="1" colspan="1">20</td><td align="center" valign="middle" rowspan="1" colspan="1">33</td><td align="center" valign="middle" rowspan="1" colspan="1">15</td><td align="center" valign="middle" rowspan="1" colspan="1">48</td><td align="center" valign="middle" rowspan="1" colspan="1">24.55</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">Characteristic</td><td align="center" valign="middle" colspan="4" rowspan="1"/><td align="center" valign="middle" rowspan="1" colspan="1">n</td><td align="center" valign="middle" rowspan="1" colspan="1">%</td></tr><tr><td align="left" valign="middle" rowspan="2" colspan="1">
<bold>Sex</bold>
</td><td align="left" valign="middle" colspan="4" rowspan="1">Male</td><td align="center" valign="middle" rowspan="1" colspan="1">71</td><td align="center" valign="middle" rowspan="1" colspan="1">59.67</td></tr><tr><td align="left" valign="middle" colspan="4" rowspan="1">Female</td><td align="center" valign="middle" rowspan="1" colspan="1">48</td><td align="center" valign="middle" rowspan="1" colspan="1">40.33</td></tr><tr><td align="left" valign="middle" rowspan="4" colspan="1">
<bold>Race</bold>
</td><td align="left" valign="middle" colspan="4" rowspan="1">White</td><td align="center" valign="middle" rowspan="1" colspan="1">88</td><td align="center" valign="middle" rowspan="1" colspan="1">73.94</td></tr><tr><td align="left" valign="middle" colspan="4" rowspan="1">Brown/Black</td><td align="center" valign="middle" rowspan="1" colspan="1">25</td><td align="center" valign="middle" rowspan="1" colspan="1">21.00</td></tr><tr><td align="left" valign="middle" colspan="4" rowspan="1">Yellow</td><td align="center" valign="middle" rowspan="1" colspan="1">2</td><td align="center" valign="middle" rowspan="1" colspan="1">1.68</td></tr><tr><td align="left" valign="middle" colspan="4" rowspan="1">Not informed</td><td align="center" valign="middle" rowspan="1" colspan="1">4</td><td align="center" valign="middle" rowspan="1" colspan="1">3.38</td></tr><tr><td align="left" valign="middle" rowspan="4" colspan="1">
<bold>Histology</bold>
</td><td align="left" valign="middle" colspan="4" rowspan="1">Undifferentiated non-keratinizing carcinoma</td><td align="center" valign="middle" rowspan="1" colspan="1">70</td><td align="center" valign="middle" rowspan="1" colspan="1">58.82</td></tr><tr><td align="left" valign="middle" colspan="4" rowspan="1">Keratinizing squamous cell carcinoma</td><td align="center" valign="middle" rowspan="1" colspan="1">40</td><td align="center" valign="middle" rowspan="1" colspan="1">33.61</td></tr><tr><td align="left" valign="middle" colspan="4" rowspan="1">Differentiated non-keratinizing carcinoma</td><td align="center" valign="middle" rowspan="1" colspan="1">6</td><td align="center" valign="middle" rowspan="1" colspan="1">5.04</td></tr><tr><td align="left" valign="middle" colspan="4" rowspan="1">Unavailable</td><td align="center" valign="middle" rowspan="1" colspan="1">3</td><td align="center" valign="middle" rowspan="1" colspan="1">2.53</td></tr><tr><td align="left" valign="middle" rowspan="4" colspan="1">
<bold>EBV</bold>
</td><td align="left" valign="middle" colspan="4" rowspan="1">Positive</td><td align="center" valign="middle" rowspan="1" colspan="1">55</td><td align="center" valign="middle" rowspan="1" colspan="1">46.21</td></tr><tr><td align="left" valign="middle" colspan="4" rowspan="1">Negative</td><td align="center" valign="middle" rowspan="1" colspan="1">20</td><td align="center" valign="middle" rowspan="1" colspan="1">16.80</td></tr><tr><td align="left" valign="middle" colspan="4" rowspan="1">Inconclusive</td><td align="center" valign="middle" rowspan="1" colspan="1">1</td><td align="center" valign="middle" rowspan="1" colspan="1">0.85</td></tr><tr><td align="left" valign="middle" colspan="4" rowspan="1">Unavailable</td><td align="center" valign="middle" rowspan="1" colspan="1">43</td><td align="center" valign="middle" rowspan="1" colspan="1">36.14</td></tr><tr><td align="left" valign="middle" rowspan="2" colspan="1">
<bold>Smoking</bold>
</td><td align="left" valign="middle" colspan="4" rowspan="1">No</td><td align="center" valign="middle" rowspan="1" colspan="1">64</td><td align="center" valign="middle" rowspan="1" colspan="1">53.78</td></tr><tr><td align="left" valign="middle" colspan="4" rowspan="1">Yes</td><td align="center" valign="middle" rowspan="1" colspan="1">55</td><td align="center" valign="middle" rowspan="1" colspan="1">46.22</td></tr><tr><td align="left" valign="middle" rowspan="5" colspan="1">
<bold>ECOG-PS</bold>
</td><td align="left" valign="middle" colspan="4" rowspan="1">0</td><td align="center" valign="middle" rowspan="1" colspan="1">33</td><td align="center" valign="middle" rowspan="1" colspan="1">27.73</td></tr><tr><td align="left" valign="middle" colspan="4" rowspan="1">1</td><td align="center" valign="middle" rowspan="1" colspan="1">68</td><td align="center" valign="middle" rowspan="1" colspan="1">57.14</td></tr><tr><td align="left" valign="middle" colspan="4" rowspan="1">2</td><td align="center" valign="middle" rowspan="1" colspan="1">14</td><td align="center" valign="middle" rowspan="1" colspan="1">11.76</td></tr><tr><td align="left" valign="middle" colspan="4" rowspan="1">3</td><td align="center" valign="middle" rowspan="1" colspan="1">3</td><td align="center" valign="middle" rowspan="1" colspan="1">2.52</td></tr><tr><td align="left" valign="middle" colspan="4" rowspan="1">Unavailable</td><td align="center" valign="middle" rowspan="1" colspan="1">1</td><td align="center" valign="middle" rowspan="1" colspan="1">0.85</td></tr><tr><td align="left" valign="middle" rowspan="2" colspan="1">
<bold>TNM staging</bold>
</td><td align="left" valign="middle" colspan="4" rowspan="1">III</td><td align="center" valign="middle" rowspan="1" colspan="1">34</td><td align="center" valign="middle" rowspan="1" colspan="1">28.58</td></tr><tr><td align="left" valign="middle" colspan="4" rowspan="1">IV</td><td align="center" valign="middle" rowspan="1" colspan="1">85</td><td align="center" valign="middle" rowspan="1" colspan="1">71.42</td></tr><tr><td align="left" valign="middle" rowspan="6" colspan="1">
<bold>ICT regimen</bold>
</td><td align="left" valign="middle" colspan="4" rowspan="1">CG</td><td align="center" valign="middle" rowspan="1" colspan="1">49</td><td align="center" valign="middle" rowspan="1" colspan="1">41.17</td></tr><tr><td align="left" valign="middle" colspan="4" rowspan="1">CF</td><td align="center" valign="middle" rowspan="1" colspan="1">31</td><td align="center" valign="middle" rowspan="1" colspan="1">26.05</td></tr><tr><td align="left" valign="middle" colspan="4" rowspan="1">TPF</td><td align="center" valign="middle" rowspan="1" colspan="1">25</td><td align="center" valign="middle" rowspan="1" colspan="1">21.00</td></tr><tr><td align="left" valign="middle" colspan="4" rowspan="1">CP</td><td align="center" valign="middle" rowspan="1" colspan="1">7</td><td align="center" valign="middle" rowspan="1" colspan="1">5.90</td></tr><tr><td align="left" valign="middle" colspan="4" rowspan="1">Carboplatin + 5FU</td><td align="center" valign="middle" rowspan="1" colspan="1">5</td><td align="center" valign="middle" rowspan="1" colspan="1">4.20</td></tr><tr><td align="left" valign="middle" colspan="4" rowspan="1">Other</td><td align="center" valign="middle" rowspan="1" colspan="1">2</td><td align="center" valign="middle" rowspan="1" colspan="1">1.68</td></tr><tr><td align="left" valign="middle" rowspan="3" colspan="1">
<bold>Subsequent therapy</bold>
</td><td align="left" valign="middle" colspan="4" rowspan="1">CRT</td><td align="center" valign="middle" rowspan="1" colspan="1">106</td><td align="center" valign="middle" rowspan="1" colspan="1">89.08</td></tr><tr><td align="left" valign="middle" colspan="4" rowspan="1">RT</td><td align="center" valign="middle" rowspan="1" colspan="1">9</td><td align="center" valign="middle" rowspan="1" colspan="1">7.56</td></tr><tr><td align="left" valign="middle" colspan="4" rowspan="1">None</td><td align="center" valign="middle" rowspan="1" colspan="1">4</td><td align="center" valign="middle" rowspan="1" colspan="1">3.36</td></tr><tr><td align="left" valign="middle" rowspan="2" colspan="1">
<bold>Concurrent Chemotherapy</bold>
</td><td align="left" valign="middle" colspan="4" rowspan="1">Cisplatin 100 mg q3w &#x000d7;3</td><td align="center" valign="middle" rowspan="1" colspan="1">104</td><td align="center" valign="middle" rowspan="1" colspan="1">98.11</td></tr><tr><td align="left" valign="middle" colspan="4" rowspan="1">Cisplatin 40 mg q1w &#x000d7;6</td><td align="center" valign="middle" rowspan="1" colspan="1">2</td><td align="center" valign="middle" rowspan="1" colspan="1">1.88</td></tr></tbody></table><table-wrap-foot><p>LA-NPC: Locally advanced nasopharyngeal carcinoma, ICT: induction chemotherapy, SD: standard deviation, ECOG: Eastern Cooperative Oncology Group performance status, CRT: chemoradiotherapy, RT: radiotherapy, TPF: docetaxel, cisplatin and 5-fluorouracil, CG: Cisplatin + Gemcitabine, CF: Cisplatin + 5-fluorouracil</p></table-wrap-foot></table-wrap><table-wrap position="float" id="table2"><label>Table 2.</label><caption><title>Descriptive table of toxicity for patients diagnosed with LA-NPC by each ICT regimen.</title></caption><table frame="border" rules="all"><thead><tr><th align="center" valign="top" rowspan="1" colspan="1"/><th align="center" valign="top" rowspan="1" colspan="1">TPF (%)<break/><italic>N</italic> = 25</th><th align="center" valign="top" rowspan="1" colspan="1">CG (%)<break/><italic>N</italic> = 49</th><th align="center" valign="top" rowspan="1" colspan="1">CF (%)<break/><italic>N</italic> = 31</th><th align="center" valign="top" rowspan="1" colspan="1">Other (%)<break/><italic>N</italic> = 14</th><th align="center" valign="top" rowspan="1" colspan="1">All (%)<break/><italic>N</italic> = 119</th><th align="center" valign="top" rowspan="1" colspan="1"><italic>p</italic> value</th></tr></thead><tbody><tr><td align="left" valign="top" rowspan="1" colspan="1">Weight loss &#x02265;10%</td><td align="left" valign="top" rowspan="1" colspan="1"/><td align="left" valign="top" rowspan="1" colspan="1"/><td align="left" valign="top" rowspan="1" colspan="1"/><td align="left" valign="top" rowspan="1" colspan="1"/><td align="left" valign="top" rowspan="1" colspan="1"/><td align="left" valign="top" rowspan="1" colspan="1"/></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Yes</td><td align="center" valign="top" rowspan="1" colspan="1">17 (68.00)</td><td align="center" valign="top" rowspan="1" colspan="1">33 (67.35)</td><td align="center" valign="top" rowspan="1" colspan="1">25 (80.65)</td><td align="center" valign="top" rowspan="1" colspan="1">8 (57.14)</td><td align="center" valign="top" rowspan="1" colspan="1">83 (69.70)</td><td align="center" valign="top" rowspan="1" colspan="1">0.37</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">No</td><td align="center" valign="top" rowspan="1" colspan="1">8 (32.00)</td><td align="center" valign="top" rowspan="1" colspan="1">16 (32.65)</td><td align="center" valign="top" rowspan="1" colspan="1">6 (19.35)</td><td align="center" valign="top" rowspan="1" colspan="1">6 (42.86)</td><td align="center" valign="top" rowspan="1" colspan="1">36 (30.30)</td><td align="left" valign="top" rowspan="1" colspan="1"/></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Severe mucositis</td><td align="left" valign="top" rowspan="1" colspan="1"/><td align="left" valign="top" rowspan="1" colspan="1"/><td align="left" valign="top" rowspan="1" colspan="1"/><td align="left" valign="top" rowspan="1" colspan="1"/><td align="left" valign="top" rowspan="1" colspan="1"/><td align="left" valign="top" rowspan="1" colspan="1"/></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Yes</td><td align="center" valign="top" rowspan="1" colspan="1">16 (64.00)</td><td align="center" valign="top" rowspan="1" colspan="1">21 (42.86)</td><td align="center" valign="top" rowspan="1" colspan="1">19 (61.29)</td><td align="center" valign="top" rowspan="1" colspan="1">8 (57.14)</td><td align="center" valign="top" rowspan="1" colspan="1">64 (53.80)</td><td align="center" valign="top" rowspan="1" colspan="1">0.25</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">No</td><td align="center" valign="top" rowspan="1" colspan="1">9 (36.00)</td><td align="center" valign="top" rowspan="1" colspan="1">28 (57.14)</td><td align="center" valign="top" rowspan="1" colspan="1">12 (38.71)</td><td align="center" valign="top" rowspan="1" colspan="1">6 (42.86)</td><td align="center" valign="top" rowspan="1" colspan="1">55 (46.20)</td><td align="left" valign="top" rowspan="1" colspan="1"/></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Enteral feeding</td><td align="left" valign="top" rowspan="1" colspan="1"/><td align="left" valign="top" rowspan="1" colspan="1"/><td align="left" valign="top" rowspan="1" colspan="1"/><td align="left" valign="top" rowspan="1" colspan="1"/><td align="left" valign="top" rowspan="1" colspan="1"/><td align="left" valign="top" rowspan="1" colspan="1"/></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Yes</td><td align="center" valign="top" rowspan="1" colspan="1">8 (32.00)</td><td align="center" valign="top" rowspan="1" colspan="1">13 (26.53)</td><td align="center" valign="top" rowspan="1" colspan="1">11 (35.48)</td><td align="center" valign="top" rowspan="1" colspan="1">6 (42.86)</td><td align="center" valign="top" rowspan="1" colspan="1">38 (31.90)</td><td align="center" valign="top" rowspan="1" colspan="1">0.64</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">No</td><td align="center" valign="top" rowspan="1" colspan="1">17 (68.00)</td><td align="center" valign="top" rowspan="1" colspan="1">36 (73.47)</td><td align="center" valign="top" rowspan="1" colspan="1">20 (64.52)</td><td align="center" valign="top" rowspan="1" colspan="1">8 (57.14)</td><td align="center" valign="top" rowspan="1" colspan="1">81 (68.10)</td><td align="left" valign="top" rowspan="1" colspan="1"/></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Increase in creatinine<xref rid="table2_fn1" ref-type="table-fn">*</xref></td><td align="left" valign="top" rowspan="1" colspan="1"/><td align="left" valign="top" rowspan="1" colspan="1"/><td align="left" valign="top" rowspan="1" colspan="1"/><td align="left" valign="top" rowspan="1" colspan="1"/><td align="left" valign="top" rowspan="1" colspan="1"/><td align="left" valign="top" rowspan="1" colspan="1"/></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Yes</td><td align="center" valign="top" rowspan="1" colspan="1">0 (0.00)</td><td align="center" valign="top" rowspan="1" colspan="1">7 (14.29)</td><td align="center" valign="top" rowspan="1" colspan="1">3 (9.68)</td><td align="center" valign="top" rowspan="1" colspan="1">2 (14.29)</td><td align="center" valign="top" rowspan="1" colspan="1">12 (10.10)</td><td align="center" valign="top" rowspan="1" colspan="1">0.20</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">No</td><td align="center" valign="top" rowspan="1" colspan="1">25 (100.00)</td><td align="center" valign="top" rowspan="1" colspan="1">42 (85.71)</td><td align="center" valign="top" rowspan="1" colspan="1">28 (90.32)</td><td align="center" valign="top" rowspan="1" colspan="1">12 (85.71)</td><td align="center" valign="top" rowspan="1" colspan="1">107 (89.90)</td><td align="left" valign="top" rowspan="1" colspan="1"/></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Febrile neutropenia</td><td align="left" valign="top" rowspan="1" colspan="1"/><td align="left" valign="top" rowspan="1" colspan="1"/><td align="left" valign="top" rowspan="1" colspan="1"/><td align="left" valign="top" rowspan="1" colspan="1"/><td align="left" valign="top" rowspan="1" colspan="1"/><td align="left" valign="top" rowspan="1" colspan="1"/></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Yes</td><td align="center" valign="top" rowspan="1" colspan="1">1 (4.00)</td><td align="center" valign="top" rowspan="1" colspan="1">3 (6.12)</td><td align="center" valign="top" rowspan="1" colspan="1">3 (9.68)</td><td align="center" valign="top" rowspan="1" colspan="1">0 (0.00)</td><td align="center" valign="top" rowspan="1" colspan="1">7 (5.90)</td><td align="center" valign="top" rowspan="1" colspan="1">0.73</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">No</td><td align="center" valign="top" rowspan="1" colspan="1">24 (96.00)</td><td align="center" valign="top" rowspan="1" colspan="1">46 (93.88)</td><td align="center" valign="top" rowspan="1" colspan="1">28 (90.32)</td><td align="center" valign="top" rowspan="1" colspan="1">14(100.00)</td><td align="center" valign="top" rowspan="1" colspan="1">112(94.10)</td><td align="left" valign="top" rowspan="1" colspan="1"/></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">SAEs</td><td align="left" valign="top" rowspan="1" colspan="1"/><td align="left" valign="top" rowspan="1" colspan="1"/><td align="left" valign="top" rowspan="1" colspan="1"/><td align="left" valign="top" rowspan="1" colspan="1"/><td align="left" valign="top" rowspan="1" colspan="1"/><td align="left" valign="top" rowspan="1" colspan="1"/></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Yes</td><td align="center" valign="top" rowspan="1" colspan="1">5 (20.00)</td><td align="center" valign="top" rowspan="1" colspan="1">9 (18.37)</td><td align="center" valign="top" rowspan="1" colspan="1">7 (22.58)</td><td align="center" valign="top" rowspan="1" colspan="1">6 (42.86)</td><td align="center" valign="top" rowspan="1" colspan="1">27 (22.70)</td><td align="center" valign="top" rowspan="1" colspan="1">0.29</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">No</td><td align="center" valign="top" rowspan="1" colspan="1">20 (80.00)</td><td align="center" valign="top" rowspan="1" colspan="1">40 (81.63)</td><td align="center" valign="top" rowspan="1" colspan="1">24 (77.42)</td><td align="center" valign="top" rowspan="1" colspan="1">8 (57.14)</td><td align="center" valign="top" rowspan="1" colspan="1">92 (77.30)</td><td align="left" valign="top" rowspan="1" colspan="1"/></tr></tbody></table><table-wrap-foot><fn id="table2_fn1"><label>*</label><p>Increase in creatinine levels &#x02265;2 mg/dL</p></fn><p>ICT: Induction chemotherapy, TPF: docetaxel, cisplatin and 5-fluorouracil, CG: Cisplatin + Gemcitabine, CF: Cisplatin + 5-fluorouracil</p></table-wrap-foot></table-wrap><table-wrap position="float" id="table3"><label>Table 3.</label><caption><title>Outcomes of patients diagnosed with LA-NPC treated with ICT.</title></caption><table frame="border" rules="all"><thead><tr><th align="center" valign="top" rowspan="1" colspan="1">Outcomes</th><th align="center" valign="top" rowspan="1" colspan="1"/><th align="center" valign="top" rowspan="1" colspan="1">
<italic>n</italic>
</th><th align="center" valign="top" rowspan="1" colspan="1">%</th></tr></thead><tbody><tr><td align="left" valign="top" rowspan="5" colspan="1">Treatment response</td><td align="left" valign="top" rowspan="1" colspan="1">PR</td><td align="center" valign="top" rowspan="1" colspan="1">32</td><td align="center" valign="top" rowspan="1" colspan="1">26.90</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">CR</td><td align="center" valign="top" rowspan="1" colspan="1">70</td><td align="center" valign="top" rowspan="1" colspan="1">58.82</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">SD</td><td align="center" valign="top" rowspan="1" colspan="1">2</td><td align="center" valign="top" rowspan="1" colspan="1">1.68</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">PD</td><td align="center" valign="top" rowspan="1" colspan="1">7</td><td align="center" valign="top" rowspan="1" colspan="1">5.88</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Unavailable</td><td align="center" valign="top" rowspan="1" colspan="1">8</td><td align="center" valign="top" rowspan="1" colspan="1">6.72</td></tr><tr><td align="left" valign="top" rowspan="2" colspan="1">Complete CRT</td><td align="left" valign="top" rowspan="1" colspan="1">No</td><td align="center" valign="top" rowspan="1" colspan="1">44</td><td align="center" valign="top" rowspan="1" colspan="1">41.90</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Yes</td><td align="center" valign="top" rowspan="1" colspan="1">62</td><td align="center" valign="top" rowspan="1" colspan="1">58.10</td></tr><tr><td align="left" valign="top" rowspan="5" colspan="1">Reason for incomplete CRT*</td><td align="left" valign="top" rowspan="1" colspan="1">Toxicity</td><td align="center" valign="top" rowspan="1" colspan="1">33</td><td align="center" valign="top" rowspan="1" colspan="1">75</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Death</td><td align="center" valign="top" rowspan="1" colspan="1">1</td><td align="center" valign="top" rowspan="1" colspan="1">2.28</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Lost follow-up</td><td align="center" valign="top" rowspan="1" colspan="1">3</td><td align="center" valign="top" rowspan="1" colspan="1">6.82</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Other</td><td align="center" valign="top" rowspan="1" colspan="1">2</td><td align="center" valign="top" rowspan="1" colspan="1">4.54</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Unavaliable</td><td align="center" valign="top" rowspan="1" colspan="1">5</td><td align="center" valign="top" rowspan="1" colspan="1">11.36</td></tr><tr><td align="left" valign="top" rowspan="2" colspan="1">Recurrence</td><td align="left" valign="top" rowspan="1" colspan="1">No</td><td align="center" valign="top" rowspan="1" colspan="1">75</td><td align="center" valign="top" rowspan="1" colspan="1">63.02</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Yes</td><td align="center" valign="top" rowspan="1" colspan="1">44</td><td align="center" valign="top" rowspan="1" colspan="1">36.98</td></tr><tr><td align="left" valign="top" rowspan="3" colspan="1">Recurrence type</td><td align="left" valign="top" rowspan="1" colspan="1">Distance</td><td align="center" valign="top" rowspan="1" colspan="1">28</td><td align="center" valign="top" rowspan="1" colspan="1">63.64</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Locorregional only</td><td align="center" valign="top" rowspan="1" colspan="1">13</td><td align="center" valign="top" rowspan="1" colspan="1">29.54</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Both</td><td align="center" valign="top" rowspan="1" colspan="1">3</td><td align="center" valign="top" rowspan="1" colspan="1">6.82</td></tr><tr><td align="left" valign="top" colspan="4" rowspan="1"/></tr></tbody></table><table-wrap-foot><p>LA-*Among patients who did not complete the chemoradiotherapy treatment</p><p>NPC: Locally advanced nasopharyngeal carcinoma, ICT: induction chemotherapy, ECOG: Eastern Cooperative Oncology Group performance status, CRT: chemoradiotherapy, RT: radiotherapy, PR: partial response, CR: complete response, SD: stable disease, PD: progressive disease</p></table-wrap-foot></table-wrap><table-wrap position="float" id="table4"><label>Table 4.</label><caption><title>Univariate analysis of patients with LA-NPC with RD after ICT and CRT or RT.</title></caption><table frame="border" rules="all"><thead><tr><th align="center" valign="top" rowspan="1" colspan="1">Variable</th><th align="center" valign="top" rowspan="1" colspan="1">% RD</th><th align="center" valign="top" rowspan="1" colspan="1">OR</th><th align="center" valign="top" rowspan="1" colspan="1">CI 95%</th><th align="center" valign="top" rowspan="1" colspan="1"><italic>p</italic>-value</th></tr></thead><tbody><tr><td align="left" valign="top" rowspan="1" colspan="1">Stage IV</td><td align="center" valign="top" rowspan="1" colspan="1">49.4</td><td align="center" valign="top" rowspan="1" colspan="1">3.77</td><td align="center" valign="top" rowspan="1" colspan="1">1.54&#x02013;10.2</td><td align="center" valign="top" rowspan="1" colspan="1">0.005</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">TPF</td><td align="center" valign="top" rowspan="1" colspan="1">32</td><td align="center" valign="top" rowspan="1" colspan="1">1</td><td align="left" valign="top" rowspan="1" colspan="1"/><td align="left" valign="top" rowspan="1" colspan="1"/></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">CG</td><td align="center" valign="top" rowspan="1" colspan="1">42.9</td><td align="center" valign="top" rowspan="1" colspan="1">1.59</td><td align="center" valign="top" rowspan="1" colspan="1">0.58&#x02013;4.55</td><td align="center" valign="top" rowspan="1" colspan="1">0.37</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">CF</td><td align="center" valign="top" rowspan="1" colspan="1">42</td><td align="center" valign="top" rowspan="1" colspan="1">1.53</td><td align="center" valign="top" rowspan="1" colspan="1">0.51&#x02013;4.75</td><td align="center" valign="top" rowspan="1" colspan="1">0.44</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Others</td><td align="center" valign="top" rowspan="1" colspan="1">50</td><td align="center" valign="top" rowspan="1" colspan="1">2.12</td><td align="center" valign="top" rowspan="1" colspan="1">0.55&#x02013;8.40</td><td align="center" valign="top" rowspan="1" colspan="1">0.27</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">EBV negative</td><td align="center" valign="top" rowspan="1" colspan="1">35</td><td align="center" valign="top" rowspan="1" colspan="1">1</td><td align="center" valign="top" rowspan="1" colspan="1">-</td><td align="center" valign="top" rowspan="1" colspan="1">-</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">EBV positive</td><td align="center" valign="top" rowspan="1" colspan="1">34.6</td><td align="center" valign="top" rowspan="1" colspan="1">0.98</td><td align="center" valign="top" rowspan="1" colspan="1">0.34&#x02013;2.99</td><td align="center" valign="top" rowspan="1" colspan="1">0.97</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">EBV unknow</td><td align="center" valign="top" rowspan="1" colspan="1">52.2</td><td align="center" valign="top" rowspan="1" colspan="1">0.53</td><td align="center" valign="top" rowspan="1" colspan="1">0.69&#x02013;6.33</td><td align="center" valign="top" rowspan="1" colspan="1">0.20</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Occurrence of SAE</td><td align="center" valign="top" rowspan="1" colspan="1">63</td><td align="center" valign="top" rowspan="1" colspan="1">3.19</td><td align="center" valign="top" rowspan="1" colspan="1">1.33&#x02013;8.01</td><td align="center" valign="top" rowspan="1" colspan="1">0.01</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">ECOG-PS &#x02265; 2</td><td align="center" valign="top" rowspan="1" colspan="1">72.2</td><td align="center" valign="top" rowspan="1" colspan="1">4.69</td><td align="center" valign="top" rowspan="1" colspan="1">1.63&#x02013;15.61</td><td align="center" valign="top" rowspan="1" colspan="1">0.006</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Keratinizing histology</td><td align="center" valign="top" rowspan="1" colspan="1">42.5</td><td align="center" valign="top" rowspan="1" colspan="1">1</td><td align="center" valign="top" rowspan="1" colspan="1">-</td><td align="center" valign="top" rowspan="1" colspan="1">-</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Non-keratinizing histology</td><td align="center" valign="top" rowspan="1" colspan="1">40.5</td><td align="center" valign="top" rowspan="1" colspan="1">0.92</td><td align="center" valign="top" rowspan="1" colspan="1">0.43&#x02013;2.01</td><td align="center" valign="top" rowspan="1" colspan="1">0.9</td></tr></tbody></table><table-wrap-foot><p>OR: Odds ratio, LA-NPC: Locally advanced nasopharyngeal carcinoma, RD: residual disease, ICT: induction chemotherapy, CRT: chemoradiotherapy, EBV: Epstein Barr virus, ECOG: Eastern Cooperative Oncology Group performance status, TPF: docetaxel, cisplatin and 5-fluorouracil, CG: Cisplatin + Gemcitabine, CF: Cisplatin + 5-fluorouracil, SAE: Serious adverse event</p></table-wrap-foot></table-wrap><table-wrap position="float" id="table5"><label>Table 5.</label><caption><title>Univariate Cox regression for variables associated with OS among patients with LA-NPC.</title></caption><table frame="border" rules="all"><thead><tr><th align="center" valign="top" rowspan="1" colspan="1">Chemotherapy regimen</th><th align="center" valign="top" rowspan="1" colspan="1">HR (CI 95%)</th><th align="center" valign="top" rowspan="1" colspan="1"><italic>p</italic>-value</th></tr></thead><tbody><tr><td align="left" valign="top" rowspan="1" colspan="1">TPF</td><td align="left" valign="top" rowspan="1" colspan="1">Ref</td><td align="center" valign="top" rowspan="1" colspan="1">0.5</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">CG</td><td align="center" valign="top" rowspan="1" colspan="1">1.2 (0.5&#x02013;2.8)</td><td align="center" valign="top" rowspan="1" colspan="1">-</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">CF</td><td align="center" valign="top" rowspan="1" colspan="1">1.8 (0.8&#x02013;4.3)</td><td align="center" valign="top" rowspan="1" colspan="1">-</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Other</td><td align="center" valign="top" rowspan="1" colspan="1">1.3 (0.4&#x02013;4.0)</td><td align="center" valign="top" rowspan="1" colspan="1">-</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">ECOG &#x02265; 2</td><td align="center" valign="top" rowspan="1" colspan="1">2.8 (1.4&#x02013;5.7)</td><td align="center" valign="top" rowspan="1" colspan="1">0.004</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">RD</td><td align="center" valign="top" rowspan="1" colspan="1">7.4 (3.8&#x02013;14.3)</td><td align="center" valign="top" rowspan="1" colspan="1">&#x0003c;0.001</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Recurrence</td><td align="center" valign="top" rowspan="1" colspan="1">6.8 (3.4&#x02013;13.4)</td><td align="center" valign="top" rowspan="1" colspan="1">&#x0003c;0.001</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">SAEs</td><td align="center" valign="top" rowspan="1" colspan="1">1.5 (0.79&#x02013;3.0)</td><td align="center" valign="top" rowspan="1" colspan="1">0.2</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Incomplete CRT</td><td align="center" valign="top" rowspan="1" colspan="1">1.1 (0.54&#x02013;2.1)</td><td align="center" valign="top" rowspan="1" colspan="1">0.8</td></tr></tbody></table><table-wrap-foot><p>HR: Hazard ratio, ECOG: Eastern Cooperative Oncology Group performance status, TPF: docetaxel, cisplatin and 5-fluorouracil, CG: Cisplatin + Gemcitabine, CF: Cisplatin + 5-fluorouracil, CRT: chemoradiotherapy</p></table-wrap-foot></table-wrap></floats-group></article>